Europe

Vaccitech, which developed the technology underlying Oxford’s covid vaccine, has priced its shares and will raise more than $110m in its IPO.

Novo Seeds co-led a $61.7m round for the oncology therapy developer to help commercialise research originating at University of Copenhagen and Rigshospitalet.

Historically left behind by their peers in the golden triangle, universities in the north are stepping up with their own funds, accelerators and collaborations.

Chief executive Antonin de Fougerolles talks about Evox’s journey to commercialising a new modality that could prove truly transformational.

The University of Bristol spinout is working on adapting cell therapies to solid tumours.

Less than two months after closing a $100m series C round, the Durham spinout has raised $225m in a series D led by SoftBank Vision Fund 2.

Diarmuid O’Brien will take over as chief executive of Cambridge Enterprise this September following the retirement of Tony Raven.

Historically left behind by their peers in the golden triangle, universities in the north are stepping up with their own funds, accelerators and collaborations.

Four of the incubator’s portfolio companies will pitch to investors at the GCV Digital Forum 3.0 following the success of similar competitions at our previous events.

Tony Raven, CEO of Cambridge Enterprise and a GUV Lifetime Achievement awardee, will step down by the end of next year.